Retatrutide Real Results: Weight Loss Timeline & What Patients Report

Introduction

Retatrutide’s Phase 2 trial produced the largest mean weight loss ever recorded in a GLP-1-class obesity study. At 48 weeks, patients on 12 mg lost an average of 24.2 percent of body weight. Nearly half lost 25 percent or more. The curve still hadn’t plateaued by trial end (Jastreboff et al. 2023 NEJM).

This article translates those trial numbers into what individual patients can expect month by month. The data comes from Jastreboff 2023, the published trial supplement, and Phase 1 PK/PD data from Coskun et al. 2022 Cell Metabolism. Real-world results will only exist after FDA approval, which Eli Lilly expects to pursue in late 2026.

While retatrutide moves through approval, TrimRx offers compounded semaglutide and tirzepatide through licensed US pharmacies, with weight loss data that’s already public from the STEP and SURMOUNT trial programs.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Much Weight Do You Lose on Retatrutide?

Phase 2 mean weight loss at 48 weeks by dose:

Quick Answer: Average weight loss at 48 weeks on 12 mg: 24.2% (Jastreboff et al. 2023 NEJM)

• Placebo: 2.1%
• 1 mg: 8.7%
• 4 mg: 17.1%
• 8 mg: 22.8%
• 12 mg: 24.2%

For a 100 kg (220 lb) patient, that’s a 24.2 kg (53 lb) average loss at the top dose by week 48. The Phase 3 trials are testing whether continued treatment to 72 weeks adds another 4 to 8 percentage points, which would put 12 mg in the 28 to 32 percent territory.

These are mean values. Individual variation is significant. Roughly 15 to 20 percent of 12 mg patients lost less than 15 percent of body weight at 48 weeks, classified as partial responders. About 10 to 15 percent lost 30 percent or more, classified as super responders.

What Does the Weight Loss Timeline Look Like Week by Week?

The Phase 2 trial reported weights at baseline, week 4, week 12, week 24, week 36, and week 48. Approximate mean cumulative loss on the 12 mg arm:

• Week 4 (still on 2 mg): 2 to 3%
• Week 8 (on 4 mg): 5 to 7%
• Week 12 (on 8 mg): 9 to 11%
• Week 24 (on 12 mg): 16 to 18%
• Week 36: 21 to 22%
• Week 48: 24.2%

The steepest weight loss happens between weeks 8 and 24, during the 4 mg, 8 mg, and 12 mg titration steps. Loss continues at roughly 0.3 to 0.5 percent per week through week 48 on maintenance dose without plateau.

When Do Retatrutide Results Start Showing?

Most patients see scale movement within the first 2 to 4 weeks. Average loss at week 4 in Phase 2 was about 2 percent on placebo-adjusted basis even at the starting 2 mg dose. By week 8, the gap to placebo was already 4 to 6 percentage points at the 4 mg dose.

Subjective changes often come even faster. Many patients in Phase 2 reported noticeable appetite suppression within 5 to 7 days of the first injection. Food preferences shift in the same window, with reduced craving for high-fat or high-sugar foods.

Body composition changes accompany the weight loss. DEXA substudies showed about 70 percent of weight lost was fat mass and 30 percent was lean tissue. Resistance training during treatment improves that ratio meaningfully.

How Does Retatrutide Compare to Tirzepatide and Semaglutide on Timeline?

Approximate 48-week comparisons across the three drugs’ top-dose Phase 3 trials:

• Semaglutide 2.4 mg (STEP 1, Wilding 2021 NEJM): about 14.5% at week 48 (final 14.9% at week 68)
• Tirzepatide 15 mg (SURMOUNT-1, Jastreboff 2022 NEJM): about 18% at week 48 (final 20.9% at week 72)
• Retatrutide 12 mg (Phase 2, Jastreboff 2023 NEJM): 24.2% at week 48

The gap between drugs is roughly 4 to 6 percentage points at each step up. Semaglutide curves had largely plateaued by week 48 in STEP 1. Tirzepatide curves were still falling slightly. Retatrutide curves were still falling steeply.

These are cross-trial comparisons. A direct head-to-head trial would be the only way to be certain. Lilly has signaled openness to such trials but none are publicly enrolled yet.

What About Waist Circumference and Body Fat Distribution?

Phase 2 secondary endpoints included waist circumference reduction, which averaged 18 to 19 cm at the 12 mg dose compared with 4 cm on placebo at 48 weeks. That’s a real change in body shape, not just scale weight.

Liver fat reduction was striking. MRI substudies in patients with baseline hepatic steatosis showed liver fat reductions of 80 percent or more on the 8 and 12 mg doses. This matches and may exceed what tirzepatide produced in the SYNERGY-NASH Phase 2 trial.

Visceral fat (the metabolically dangerous abdominal fat around organs) decreased disproportionately to subcutaneous fat. That pattern is associated with improvements in cardiovascular and metabolic risk markers.

Key Takeaway: Weight loss curves did not plateau by week 48 at the 8 mg or 12 mg dose

What Do Partial Responders Look Like?

In Phase 2, about 15 to 20 percent of 12 mg patients lost less than 15 percent body weight at 48 weeks. These partial responders generally:

• Had higher baseline insulin resistance and more severe obesity
• Lost weight steadily but at a slower rate
• Tolerated the drug normally without severe side effects
• May respond better to extended treatment (72+ weeks) per Phase 3 protocol

Some partial responders may be using their reduced appetite as a starting point but compensating with higher caloric intake than maximally effective. Detailed food tracking and structured dietary support cuts the partial responder rate in real-world GLP-1 use.

What Weight Loss Do Super Responders See?

About 10 to 15 percent of 12 mg patients in Phase 2 lost 30 percent or more of body weight at 48 weeks. The maximum individual loss approached 40 percent. Super responders shared a few patterns:

• Higher baseline GLP-1 sensitivity (suggested by stronger appetite suppression in week 1)
• Lower baseline lean mass relative to fat mass
• Often female with android (apple-shaped) fat distribution

There’s no validated way to predict super-responder status before treatment. Genetic markers tied to GLP-1 receptor variants are being explored but aren’t actionable clinically yet.

Will the Weight Stay Off After Stopping Retatrutide?

Probably not, based on the broader GLP-1 class data. The STEP 4 trial of semaglutide showed patients who stopped after 20 weeks regained about two-thirds of their lost weight within 48 weeks. SURMOUNT-4 showed similar tirzepatide regain.

Retatrutide will likely follow the same pattern. Treatment of obesity with GLP-1 drugs is increasingly viewed as a chronic disease management approach, similar to blood pressure or cholesterol medication, rather than a finite course.

Some patients can maintain weight on lower maintenance doses (4 mg) after reaching their target, but this hasn’t been formally trialed for retatrutide.

What Metabolic Improvements Come with the Weight Loss?

Phase 2 secondary endpoints showed at the 12 mg dose by week 48:

• HbA1c reduction: 1.6 to 2.0 percentage points in T2D patients
• LDL cholesterol: down 10 to 15%
• Triglycerides: down 25 to 35%
• Systolic blood pressure: down 7 to 10 mmHg
• Liver enzymes (ALT, AST): substantial improvements
• C-reactive protein: down 30 to 50%

These changes are typical for high-quality weight loss but the magnitudes are larger than what either semaglutide or tirzepatide produced in their key trials.

Bottom line: Phase 3 TRIUMPH trials are testing 72-week and longer-duration outcomes

FAQ

How Long Until I See Results on Retatrutide?

Most patients see appetite suppression in the first week and scale movement within 2 to 4 weeks. The fastest weight loss happens between weeks 8 and 24.

Do All Patients Respond to Retatrutide?

No. About 15 to 20 percent of Phase 2 patients on 12 mg lost less than 15 percent body weight at 48 weeks. True non-response (less than 5 percent loss) was rare but not zero.

Is Retatrutide Weight Loss Real Fat Loss or Water Weight?

Mostly fat loss. DEXA substudies showed about 70 percent of weight lost was fat mass and 30 percent lean tissue. Some initial 2 to 3 pound drop in the first week is water due to glycogen depletion.

Can I Lose More Than 25 Percent on Retatrutide?

Yes, in Phase 2 about 48 percent of 12 mg patients lost 25 percent or more by week 48, and some lost close to 40 percent. Phase 3 data with longer treatment duration may push the mean and ceiling higher.

Will I Plateau?

Phase 2 12 mg patients did not plateau by week 48 on average. Individual patients vary. Phase 3 trials will tell us whether continued treatment to 72 weeks and beyond produces additional loss or eventual plateau.

How Fast Does Weight Come Back If I Stop?

Based on semaglutide and tirzepatide stopping trials, expect to regain roughly two-thirds of lost weight within 12 months of discontinuation. Continued GLP-1 treatment maintains the loss.

Is Rapid Weight Loss Safe?

Rapid weight loss of more than 1 to 2 percent per week can stress the gallbladder and increase lean mass loss. Phase 2 retatrutide patients on 12 mg lost about 0.5 to 0.7 percent per week on average, which is rapid but generally safe with appropriate medical follow-up.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.